Introduction {#S0001}
============

Conventional anticancer therapy does not distinguish between normal and cancer cells. The damage inflicted on normal tissue have thus hampered this therapy.[@CIT0001] The introduction of targeted-therapy molecules targeting specific enzymes, growth-factor receptors, and signal transducers has lowered the incidence of side effects,[@CIT0002] significantly influencing patient quality of life and survival rates.[@CIT0002]mTOR is a therapeutic target for both solid and hematologic malignancies. It is part of a pathway that regulates protein biosynthesis, cell growth, and cell-cycle progression. Moreover, mTOR is the downstream effector of the PI3K--Akt--mTOR pathway, which regulates cell growth and metabolism and is involved in multiple processes.[@CIT0001],[@CIT0003]--[@CIT0005]

Rapamycin and its analogues form the first generation of mTOR inhibitors. The action of these molecules is targeting a 289 kDa serine/threonine-protein kinase that is a component of the big family of PI3Ks. Rapamycin and its analogues work by inhibiting the activity of mTORC1 through binding to FKBP12 and the establishment of a ternary complex with mTOR.[@CIT0006]Actually, there are three available mTOR inhibitors: everolimus, temsirolimus, and ridaforolimus. Everolimus is currently used for the treatment of advanced hormone receptor--positive HER2-negative breast cancer together with exemestane, renal-cell carcinoma after failure of therapies based on sunitinib or sorafenib, progressive neuroendocrine tumors of pancreatic origin, in combination with exemestane, and subependymal giant-cell astrocytoma.

These drugs have a different spectrum of side effects compared to conventional chemotherapy. Common side effects are anemia, fatigue, hyperglycemia, hyperlipidemia, stomatitis, rash, and thrombocytopenia.[@CIT0005],[@CIT0007] The terms "oral mucositis" and "stomatitis" are both used to describe inflammation and ulceration of the oral mucosal lining due to chemotherapy or ionizing radiation. However, stomatitis associated with mTOR inhibitors should be considered a separate entity this often being designated as mTOR inhibitor--associated stomatitis (mIAS).[@CIT0008],[@CIT0009] Mouth lesions present as superficial, ovoid, well-demarcated singular or multiple ulcers with a grayish white pseudomembrane. Their size often does not exceed 0.5 cm in diameter. Lesions typically involve the nonkeratinized mucosa, like the inner aspect of the lips, the ventral and lateral surfaces of the tongue, and the soft palate. Ulcers generally develop in 5 days and usually heal spontaneously in 1 week, most frequently in the first cycle of mTOR-inhibitor therapy.[@CIT0010]

Methods {#S0002}
=======

This review was performed to answer to the question "Which is the rate of incidence of stomatitis in patients treated with everolimus?" A systematic search on the online databases PubMed and Medline was conducted using a combination of MESH terms and free-text words: "everolimus" (MESH) AND "side effects" OR "toxicities" OR "adverse events". The authors included in this study only reports that fulfilled certain criteria: performed on human subjects, everolimus alone or in combination with other drugs/ionizing radiation, written in the English language, and providing incidence of side effects. No restrictions were applied on year of publication. Reviews, case reports, and studies in vitro or performed on animal models were excluded. Information collected comprised name of first author, year, title, number of patients enrolled, and number and grade of events recorded. In addition, data were independently extracted by two authors (CA and LLM) and checked in a joint session.

Results {#S0003}
=======

Our literature search yielded 1,019 potentially relevant studies. After elimination of duplicates, titles and abstracts of 912 potentially relevant studies were screened. Of these, 731 were not considered because they did not meet the inclusion criteria. A total of 181 studies were read in full text. Of these, only 100 reported on stomatitis or oral mucositis, and 30 were excluded due to lack of data ([Figure 1](#F0001){ref-type="fig"}). Results howed that the overall incidence of stomatitis after treatment with everolimus was 42.6% (3,493), stomatitis grade G12 84.02% (2,935), and G34 15.97% (558, [Table 1](#T0001){ref-type="table"}).Table 1Papers About Everolimus And StomatitisStudyYearTitleTherapyPatients, nStomatitis, n (%)G1/2, n (%)G3/4, n (%)Amato et al[@CIT0027]2009A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancerEverolimus at a dose of 10 mg daily orally without interruption (28-day cycle), with dose modifications for toxicity (graded according to National Cancer Institute Common Toxicity Criteria version 3.0). Patients were evaluated every two cycles (8 weeks) using Response Evaluation Criteria in Solid Tumors (RECIST)3912 (30.8)G1 4 (10.3)\
G2 8 (20.5)Andre et al[@CIT0028]2014Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trialIn this randomised, double-blind, placebo-controlled, phase III trial, authors recruited women with HER2-positive, trastuzumab-resistant advanced breast carcinoma who had previously received taxane therapy. Eligible patients were randomly assigned (1:1) using a central patient-screening and -randomization system to daily everolimus (5 mg/day) plus weekly trastuzumab (2 mg/kg) and vinorelbine (25 mg/m^2^) or to placebo plus trastuzumab plus vinorelbine, in 3-week cycles, stratified by previous lapatinib use280175 (62)138 (49)G3 37 (13)Angelousi et al[@CIT0029]2017Sequential everolimus and sunitinib treatment in pancreatic metastatic well-differentiated neuroendocrine tumours resistant to prior treatmentsA: 20 1st-line everolimus\
B: 11 2nd-line everolimusA: 20\
B: 11A: 2 (10)\
B: 1 (9)A: 2 (10)\
B: 1 (9)Armstrong et al[@CIT0030]2016Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN --- a multicentre, open-label, randomised phase 2 trial)Everolimus orally at 10 mg once daily5227 (48)22 (39)G3 5 (9)Bajetta et al[@CIT0031]2014Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumorsTreatment-naïve patients with advanced well-differentiated NETs of gastroenteropancreatic tract and lung origin received everolimus 10 mg daily in combination with octreotide LAR 30 mg every 28 days503126 (52)G3 4 (8)\
G4 1 (2)Baselga et al[@CIT0032]2012Everolimus in postmenopausal hormone-receptor--positive advanced breast cancerDouble-blind phase III study, patients randomly assigned to treatment with oral everolimus or matching placebo (10 mg daily) in conjunction with exemestane (25 mg daily)48256 (11.61)48 (9.95)G3 8Baselga et al[@CIT0033]2009Phase II randomized study of neoadjuvant everolimusplus letrozole compared with placebo plus letrozole inpatients with estrogen receptor--positive breast cancer270 postmenopausal women with operable ER-positive breast cancer were randomly assigned to receive 4 months of neoadjuvant treatment with letrozole (2.5 mg/day) and either everolimus (10 mg/day) or placebo13750 (36.5)47 (34.3)3 (2.2)Bergmann et al[@CIT0034]2015Everolimus in metastatic renal cell carcinoma after failure of initial anti--VEGF therapy: final\
results of a noninterventional studyPatients received everolimus 10 mg once daily until disease progression or unacceptable33422 (7)18 (81)4 (18)Besse et al[@CIT0035]2014Phase II study of everolimus--erlotinib in previously treated patients with advanced non-small-cell lung cancerEverolimus 5 mg/day + erlotinib 150 mg/day6648 (72.6)G1 11 (16.7) G2 16 (24.2)G3 21 (31.8)Campone et al[@CIT0036]2009Safety and pharmacokinetics of paclitaxel and the oral mTOR inhibitor everolimus in advanced solid tumoursEverolimus was dose-escalated from 15 to 30 mg and administered with paclitaxel 80 mg/m^2^ on days 1, 8, and 15 every 28 days166 (37.5)5 (31.25)G3 1 (6.25)Castellano et al[@CIT0037]2013Everolimus plus octreotide long-acting repeatable in patients with colorectal neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-2 studyEverolimus plus octreotide1911 (57.9)Chan et al[@CIT0038]2013A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumorPatients treated with temozolomide 150 mg/m^2^ per day on days 1--7 and 15--21 in combination with everolimus daily in each 28-day cycle. In cohort 1, temozolo mide was administered together with everolimus at 5 mg daily. Following demonstration of safety in this cohort, subsequent patients in cohort 2 were treated with temozolomide plus everolimus at 10 mg daily4327G1 22 (51)\
G2 4 (9)G3 1 (2)Choueiri et al[@CIT0039]2015Cabozantinib versus everolimus in advanced renal cell carcinomaEverolimus at a dose of 10 mg daily32277 (24)70 (21.7)7 (2.2)Chow et al[@CIT0040]2016A phase 2 clinical trial of everolimus plus bicalutamide for castration-resistant prostate cancerOral bicalutamide 50 mg and oral everolimus 10 mg, both once daily, with a cycle defined as 4 weeks2414 (58.3)10 (41.6)G3 4Chung et al[@CIT0041]2016Phase Ib trial of mFOLFOX6 and everolimus (NSC-733,504) in patients with metastatic gastroesophageal adenocarcinomaSix patients were accrued to the first dose level of 2.5 mg everolimus daily with mFOLFOX6A: 64 (66)G1 2 (33)G3 2 (33)Ciruelos et al[@CIT0042]2017Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in SpainEligible patients started study treatment on day 1 with daily doses of everolimus (2/5/9 mg or 1/9/10 mg) and exemestane (25 mg) and continued until disease progression or unacceptable toxicity429272 (63)232 (54)G3 40 (9)Ciunci et al[@CIT0043]2014Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancerNot reported294 (13.8)G2 4 (13.8)Colon-Otero et al[@CIT0044]2017Phase 2 trial of everolimus and letrozole in relapsed estrogen receptor-positive high-grade ovarian cancerPatients received oral everolimus 10 mg daily and letrozole 2.5 mg daily192 (10.5)G3 2 (10.5)Courtney et al[@CIT0045]2015A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancerPatients received everolimus 10 mg daily for 2 weeks and underwent a restaging FDG- PET/computed tomography scan. Patient cohorts were subsequently treated at three dose levels of everolimus with docetaxel: 5--60 mg/m^2^, 10--60 mg/m^2^, and 10--70 mg/m^2^. The primary end point was the safety and tolerability of combination therapy.185 (27.7)5 (27.7)Deenen et al[@CIT0046]2012Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignanciesFixed-dose everolimus 10 mg/day continuously plus capecitabine twice daily for 14 days in 3-weekly cycles189 (50)9 (50)Doi et al[@CIT0047]2010Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancerEverolimus 10 mg orally dailyA: 533 (5.7)Elmadani et al[@CIT0048]2017EVESOR, a model-based, multiparameter, phase I trial to optimize the benefit/toxicity ratio of everolimus and sorafenibEverolimus + sorafenib266 (23.1)6 (23.1)Escudier at al.[@CIT0049]2016Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysisOral everolimus 10 mg once daily until disease progression or unacceptable toxicity9223 (25)23 (25)Fazio et al[@CIT0050]2013Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study\
Everolimus + octreotide333 (9.1)Ferolla et al[@CIT0051]2017Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trialA: everolimus\
B: everolimus + pasireotideA: 42\
B: 41Total A: 30 (72)\
Total B: 15 (37)A: 26 (62)\
B: 13 (32)A: G3 4 (10)\
B: G3 2 (5)Finn et al[@CIT0052]2013Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinomaA: sorafenib + everolimus 2.5 mg once daily\
B: sorafenib + everolimus 5 mg once dailyA: 16\
B: 14A: 6 (37.5)\
B: 6 (42.9)\
Ulcers total 6 (37.5)A: 6 (37.5)\
B: 5 (35.8)A: 0\
B: 1 (7.1)Fury et al[@CIT0053]2012A phase I study of daily everolimus plus low-dose weekly cisplatin for patients with advanced solid tumorsNot reported3011 (39)11 (39)Ghobrial et al[@CIT0054]2010Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenström macroglobulinemiaEverolimus 10 mg daily for two cycles504 (8)4 (8)Goldberg et al[@CIT0055]2015Everolimus for the treatment of lymphangioleiomyomatosis: a phase II studyNot reported2418 (75)Gong et al[@CIT0056]2017Efficacy and safety of everolimus in Chinese metastatic HR positive, HER2 negative breast cancer patients: a real-world retrospective studyEverolimus was usually initiated at 10 mg or in some instances 5 mg daily, according to patients' tolerance and request7040 (57.1)34 (47.8)G3 6 (9.3)Grignani et al[@CIT0057]2015Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trialA: patients took 400 mg sorafenib twice a day together with 5 mg everolimus once a day3820G1 11 (29)\
G2 7 (18)G3 2 (5)Hainsworth et al[@CIT0058]2010Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinomaAll patients received bevacizumab 10 mg/kg intravenously every 2 weeks and everolimus 10 mg orally daily804836 (45)G3 12 (15)Hatano et al[@CIT0059]2016Outcomes of everolimus treatment for renal angiomyolipoma\
associated with tuberous sclerosis complex: a single institution\
experience in JapanEverolimus set at 10 mg once a day for adults4743 (91)42 (97.6)1 (2.3)Hatano et al[@CIT0060]2017Intermittent everolimus administration for renal angiomyolipoma associated with tuberous sclerosis complexEverolimus set at 10 mg once a day2623 (88)221Hurvitz et al[@CIT0061]2013A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapyEverolimus 10 mg/day in combination with paclitaxel (80 mg/m^2^ days 1, 8, and 15 every 4 weeks) and trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly), administered in 28-day cycles5542 (76.3)G1 13 (23.6)G2 18 (32.7)G3 11 (20)Jerusalem et al[@CIT0062]2016Safety of everolimus plus exemestane in patients with hormone-receptor--positive, HER2-negative locally advanced or metastatic breast cancer progressing on prior non-steroidal aromatase inhibitors: primary results of a phase IIIb, open-label, single-arm, expanded-access multicenter trial (BALLET)Not reported2,1311,126 (52.8)926 (43.4)G3 198 (9.3) G4 2 (0.1)Jovanovic et al[@CIT0063]2017A randomized phase II neoadjuvant study of cisplatin, paclitaxel with or without everolimus in patients with stage II/III triple-negative breast cancer (TNBC): responses and long-term outcome correlated with increased frequency of DNA damage response gene mutations, TNBC subtype, AR status and Ki67Not reported9637 (39)37 (39)Jozwiak et al[@CIT0064]2016Safety of everolimus in patients younger than 3 years of age: results from EXIST-1, a randomized, controlled clinical trialEverolimus initiated at 4.5 mg/m^2^/day and titrated to blood trough levels of 5--15 ng/mL1812 (66.7)Kato et al[@CIT0065]2014Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatmentNot reported197 (37)6 (32)1 (5)Kim et al[@CIT0066]2014A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinomaEverolimus given at 10 mg daily until progression or occurrence of unacceptable toxicities3427 (79.4)26 (96.2)1 (2.9)Kim et al[@CIT0067]2018Clinical outcomes of the sequential use of pazopanib followed by\
everolimus for the treatment of metastatic renal cell carcinoma:\
a multicentre study in KoreaEverolimus3615 (41.7)14 (38.9)1 (2.8)Koutsoukos et al[@CIT0068]2017Real-world experience of everolimus as second-line treatment in metastatic renal cell cancer after failure of pazopanibNot reported318 (26)G1 4 (13)\
G2 1 (3)G3 3 (10)Kulke et al[@CIT0069]2017A randomized, open-label, phase 2 study of everolimus in combination with pasireotide LAR or everolimus alone in advanced, well-differentiated, progressive pancreatic neuroendocrine tumors: COOPERATE-2 trialA: everolimus + pasireotide LAR\
B: everolimusA: 78\
B: 81A: 46 (59)\
B: 51 (63)A: 39 (50)\
B: 44 (54.4)A: 7 (9)\
B: 7 (8.6)Kumano et al[@CIT0070]2013Sequential use of mammalian target of rapamycin inhibitors\
in patients with metastatic renal cell carcinoma following failure of tyrosine kinase inhibitorsEverolimus5717 (29.8)14 (82.35)3 (5.3)Moscetti et al[@CIT0071]2016Safety analysis, association with response and previous treatments of everolimus and exemestane in 181 metastatic breast cancer patients: a multicenter Italian experienceNot reported181115 (63.5)G1 54 (29.8) G2 46 (25.4)G3 15 (8.3)Motzer et al[@CIT0072]2016Phase II trial of second-line everolimus in patients with metastatic renal cell carcinoma (RECORD-4)^†^Not reported1337 (5.26)Motzer et al[@CIT0073]2014Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinomaEverolimus23853 (22.26)47 (19.74)G3 6 (2.52)Motzer et al[@CIT0017]2008Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial\
Everolimus 10 mg once daily269107 (40)98 (36.43)G3 9 (3.34)Motzer et al[@CIT0074]2015Lenvatinib, everolimus, and the combination in patients with metastatic renal cell carcinoma: a randomised, phase 2, open-label, multicentre trialEverolimus 10 mg day5021 (42)20 (40)G3 1 (2)Oh et al[@CIT0075]2012Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomasEverolimus was administered daily at a dose of 10 mg for 4 weeks.346 (17.6)4 (11.7)2 (5.9)Ohtsu et al[@CIT0076]2013Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 studyEverolimus 10 mg/day + BSC437174 (40)154 (35)20 (5)Ohyama et al[@CIT0077]2017Efficacy and safety of sequential use\
of everolimus in Japanese patients with advanced renal cell carcinoma after failure of first-line treatment with vascular endothelial growth factor receptor tyrosine kinase inhibitor: a multicenter phase II clinical trialNot reportedA :5326 (49.1)22 (41.6)4 (7.5)Panzuto et al[@CIT0078]2014Real-world study of everolimus in advanced progressive neuroendocrine tumorsEverolimus16937 (21.9)33 (19.6)4 (2.3)Park et al[@CIT0079]2014Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma following treatment failure with a vascular endothelial growth factor receptor-tyrosine kinase inhibitor\
Everolimus10042 (44)36 (38)6 (6)Pavel et al[@CIT0080]2016Safety and QOL in patients with advanced NET in a phase 3b expanded access study of everolimusNot reported12329 (23.6)23 (18.7)G3 6 (4.9)Quek et al[@CIT0081]2011Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and\
other solid tumorsFigitumumab (20 mg/kg IV every 21 days) with full-dose everolimus (10 mg orally once daily)2121 (100)G1 11 (52.4)\
G2 7 (33.3)G3 3 (14.3)Safra et al[@CIT0082]2018Everolimus plus letrozole for treatment of patients with HR^+^, HER2^--^advanced breast cancer progressing on endocrine therapy: an open-label, phase II trialEverolimus 10 mg daily and letrozole 2.5 mg daily7239 (54.2)18 (45.9)G3 21 (8.3)Salazar et al[@CIT0083]2017Phase II study of BEZ235 versus everolimus in patients with mammalian target of rapamycin inhibitor-naïve advanced\
pancreatic neuroendocrine tumorsEverolimus 10 mg once daily3120 (64.5)18 (58)2 (6.5)Sarkaria et al[@CIT0084]2011NCCTG phase I trial N057K of everolimus (RAD001) and temozolomide in combination with radiation therapy in newly diagnosed glioblastoma multiforme patientsAll patients received weekly oral RAD001 in combination with standard chemoradiotherapy, followed by RAD001 in combination with standard adjuvant temozolomide1811 (61.1)G2 11 (61.1)Strickler et al[@CIT0085]2012Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors10 mg panobinostat three times weekly, 5 or 10 mg everolimus daily, and bevacizumab at 10 mg/kg every 2 weeks124 (33)3 (25)1 (8)Sun et al[@CIT0086]2013A phase 1b study of everolimus plus\
paclitaxel in patients with small-cell lung cancer\
A: everolimus 2.5 mg 6\
B: everolimus 5 mg 11\
C: everolimus 10 mg 3208 (40)A 2 10)\
B 5 (25)\
C 1 (5)Takahashi et al[@CIT0087]2013Efficacy and safety of concentration-controlled everolimus with reduced-dose cyclosporine in Japanese de novo renal transplant patients: 12-month resultsEverolimus 1.5 mg/day starting dose (target trough 3--8 ng/mL) + reduced-dose cyclosporine6114 (23)Tobinai et al[@CIT0088]2010Phase I study of the oral mammalian target of rapamycin inhibitor everolimus (RAD001) in Japanese patients with relapsed or refractory non-Hodgkin lymphoma\
everolimus 5 or 10 mg orally once dailyNot reported137 (53.7)G1 3 (23.7)\
G2 4 (30.7)Vlahovic et al[@CIT0089]2012A phase I study of bevacizumab, everolimus and panitumumab in advanced solid tumorsEverolimus and flat dosing of panitumumab at 4.8 mg/kg and bevacizumab at 10 mg/kg every 2 weeks3224 (76)20 (63)4 (13)Wang et al[@CIT0090]2014Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 studyNot reported5812 (20.7)11 (19)G3 1 (1.7)Werner et al[@CIT0091]2013Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinomaOral everolimus (5, 7.5, and 10 mg/day) in combination with intravenous MMC 5 mg/m^2^ every 3 weeks.169 (56.25)G1 8 (50)G3 1 (6.25)Wolpin et al[@CIT0092]2009Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancerEverolimus 10 mg daily3310 (30)G1 8 (24)\
G2 1 (3)G3 1 (3)Yao et al[@CIT0093]2008Efficacy of everolimus and octreotide LAR in advanced low- to intermediate-grade neuroendocrinetumors: results of a phase II study\
RAD001 5 mg/day or 10 mg/day and octreotide LAR 30 mg every 28 days64Aphtous ulcers 5 (8)\
Dysgeusia 1 (2)Yao et al[@CIT0094]2011Everolimus for advanced pancreatic neuroendocrine tumors10 mg once daily204131 (64)117 (57)14 (7)Yee et al[@CIT0095]2006Phase I/II study of everolimus in patients with relapsed or refractory hematologic malignanciesNot reported2710 (37)10 (37)Total over all8,2013,490 (42.55)Total with grade7,7963,347 (42.93)2,839 (36.41)508 (6.51) Figure 1Flowchart showing the process of paper selection used in this review.

Discussion {#S0004}
==========

Targeted therapy includes those drugs that selectively inhibit a target that is mutated in malignant tissue, aiming to achieve preferential localization in the region of disease and thus an increase in local concentration. In particular, mTOR inhibitors work as signal-transduction inhibitors. Rapamycin, also named sirolimus, was the first mTOR inhibitor approved. It is an antiungal agent produced by *Streptomyces* hygroscopicus with immunosuppressive properties.[@CIT0011] However, sirolimus has been show to have poor pharmacokinetic characteristics, and research has focused on the synthesis of analogues of rapamycin more suitable to therapy, such as everolimus, temsirolimus, and ridaforolimus. These molecules differ from sirolimus in their C-40-O positions, resulting in disparate pharmacokinetic and pharmacodynamic profiles.[@CIT0012] This class of drugs is typically used for the treatment of solid tumors, such as renal-cell carcinoma, breast cancer, pancreatic neuroendocrine tumors, and tuberous sclerosis complex.[@CIT0013]--[@CIT0017]

Unlike results obtained from reviews about mucositis caused by conventional chemotherapy, in which mucositis is often severe and the most debilitating effect for patients,[@CIT0018] our analysis showed that the incidence of stomatitis of grade 1 or 2 is higher than that of grade 3 or 4. These results are consistent with our previous work.[@CIT0019] However, it must be taken into account that it is not possible to say if side effects are entirely due to everolimus therapy or combination with other drugs. Moreover, not all the papers included in this review specified the exact therapeutic regimen. mIAS generally sets in within a few weeks of initiating everolimus therapy. Grade 3 or 4 lesions may lead to dose interruption or reduction. Interfering with patientfood intake and diminishing quality of life, this kind of toxicity may cause treatment discontinuation or interruption.[@CIT0020]

mIAS is often evaluated using common scales employed in the evaluation of conventional oral mucositis (OMAS, 1999; NCI-CTCAE 2006, 2010). However, its clinical appearance tends to differ from conventional mucositis. A more specific mIAS scale was set by Boers-Doets and Lalla. According to this scale, lesions are evaluated depending on their duration, eg, a grade 3 lesion is an ulceration lasting \>7 days.[@CIT0021] Management of mIAS is still widely based on education of patients on oral hygiene measures, diet modifications, and pain management.[@CIT0009],[@CIT0022] Treatments used are often based on "magic" mouthwash, composed of lidocaine gel 2% × 30 g, doxycycline suspension 50 mg/5mL × 60 mL, and sucralfate oral suspension 1,000 mg/5 mL dissolved in sodium chloride 0.9% × 2,000 mL used for 3--15 days,[@CIT0023] a sodium bicarbonate--based mouthwash combined with oral fluconazole,[@CIT0024] or a combination of dexamethasone solution 0.5 mg/mL and miconazole 2% gel.[@CIT0025] Another treatment is based on a combination of topical anesthetics, a magic mouthwash (composed of lidocaine, aluminum hydroxide, magnesium hydroxide, dimethicone suspension, diphenhydramine, equal parts) clobetasol gel 0.05%, dexamethasone 0.1 mg/mL, triamcinolone paste, intralesional triamcinolone, and systemic prednisone (1 mg/kg for 7 days). Management of mIAS nowadays is based on education of patients on oral hygiene measures, diet modifications, and pain management.[@CIT0009] Rugo et al showed evidence of the efficacy of a prophylactic use of dexamethasone mouthwash in patients treated with everolimus plus exemestane for advanced or metastatic breast cancer.[@CIT0026] The mouthwash was administered in combination with a prophylactic topical antifungal agent to prevent potential fungal infection.[@CIT0026] It still cannot be determined which lesions will self-limit and which will reduce quality of life, leading to malnutrition and dose reduction in medically necessary treatment.
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